Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.
The current price of NVAX is 8.51 USD — it has decreased by −1.39% in the past 24 hours. Watch Novavax, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Novavax, Inc. stocks are traded under the ticker NVAX.
NVAX stock has fallen by −6.99% compared to the previous week, the month change is a 5.71% rise, over the last year Novavax, Inc. has showed a 72.27% increase.
We've gathered analysts' opinions on Novavax, Inc. future price: according to them, NVAX price has a max estimate of 25.00 USD and a min estimate of 9.00 USD. Watch NVAX chart and read a more detailed Novavax, Inc. stock forecast: see what analysts think of Novavax, Inc. and suggest that you do with its stocks.
NVAX reached its all-time high on Feb 9, 2021 with the price of 331.68 USD, and its all-time low was 3.53 USD and was reached on Feb 5, 2024. View more price dynamics on NVAX chart. See other stocks reaching their highest and lowest prices.
NVAX stock is 2.49% volatile and has beta coefficient of 2.66. Track Novavax, Inc. stock price on the chart and check out the list of the most volatile stocks — is Novavax, Inc. there?
Today Novavax, Inc. has the market capitalization of 1.38 B, it has increased by 2.04% over the last week.
Yes, you can track Novavax, Inc. financials in yearly and quarterly reports right on TradingView.
Novavax, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
NVAX earnings for the last quarter are −0.76 USD per share, whereas the estimation was −0.79 USD resulting in a 3.93% surprise. The estimated earnings for the next quarter are −0.60 USD per share. See more details about Novavax, Inc. earnings.
Novavax, Inc. revenue for the last quarter amounts to 84.51 M USD, despite the estimated figure of 73.78 M USD. In the next quarter, revenue is expected to reach 102.74 M USD.
NVAX net income for the last quarter is −121.30 M USD, while the quarter before that showed 162.38 M USD of net income which accounts for −174.70% change. Track more Novavax, Inc. financial stats to get the full picture.
No, NVAX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 1.54 K employees. See our rating of the largest employees — is Novavax, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Novavax, Inc. EBITDA is −243.18 M USD, and current EBITDA margin is −38.00%. See more stats in Novavax, Inc. financial statements.
Like other stocks, NVAX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Novavax, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Novavax, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Novavax, Inc. stock shows the sell signal. See more of Novavax, Inc. technicals for a more comprehensive analysis. If you're still not sure, try looking for inspiration in our curated watchlists.